Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Integrating New Approach Methodologies (NAMs) into Read-Across Evidence Streams for Short-Chain Nitroparaffins.

Created on 21 Oct 2026

Authors

Jordan S Kozal, Madeline Streifer, Elizabeth Hofstetter, A Rasim Barutcu, Marjory Moreau, Pierre Serfass, Pamela J Spencer, Andrew Maier

Published in

Regulatory toxicology and pharmacology : RTP. Pages 106278. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

Read-across is commonly used to fill data gaps for chemical registration and safety assessment. Current read-across guidelines recommend systematic approaches for evaluating suitability of analogue data for assessing target chemical data gaps. However, these frameworks still lack practical approaches for consistently integrating diverse evidence, such as data from new approach methodologies (NAMs), into final read-across determinations. Herein, we present a case study of integration of multiple lines of evidence, including NAMs, to assess the suitability of a read-across from nitromethane (NM) to nitroethane (NE) and 1-nitroproane (1NP). The three nitroparaffins are structurally similar, which historically was considered sufficient evidence for read-across. However, data from several other lines of evidence suggest that read-across is not appropriate. The nitroparaffins differ in terms of physicochemical, toxicokinetic, toxicological, and toxicodynamic properties, as well as the identity of aldehyde metabolites. Our analysis reaffirms current guidelines that grouping chemicals based on shared functional groups alone is not a sufficient read-across justification. Further, our analysis demonstrates how NAMs can serve as a critical component to the overall evidentiary basis for read-across arguments, which will be particularly impactful in cases where extant in vivo data is insufficient to make a read-across determination with high confidence.

PMID:
42901365
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 27
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement